



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Votrient™

Common Name: Pazopanib

PDL Category: Antineoplastics- Protein-Tyrosine Kinase Inhibitors

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Afinitor®	Recommended
Nexavar®	Non-Recommended
Sutent®	Recommended

Summary

Indications and Usage: Kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma.¹

Mechanism of Action: Angiogenesis inhibitor that may prevent growth of new blood vessels, thereby blocking the growth of kidney cancer tumors dependent on blood vessels to survive.¹

Dosage Forms: Tablets: 200mg¹

Recommended Dosage: 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Baseline moderate hepatic impairment – 200 mg orally once daily. Not recommended in patients with severe hepatic impairment.¹

Common Adverse Drug Reactions: Diarrhea, hypertension, hair color changes, nausea, anorexia, vomiting.¹

Contraindications: None¹

Manufacturer: GlaxoSmithKline

Analysis: Votrient™ is a once daily oral cancer treatment for patients with advanced renal cell carcinoma. In the trial used to gain FDA approval, Votrient™ was compared only to placebo. Patients treated with Votrient™, experienced an overall median progression free survival of 9.2 months, compared to 4.2 months for placebo-treated patients. It is recommended that Votrient™ be added to the Preferred Drug List as a recommended drug as it provides an effective therapeutic alternative for the treatment of advanced renal cell carcinoma.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input checked="" type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Non-Preferred Drug with Conditions	

1. Votrient™ [package insert]. Research Triangle Park, NC: GlaxoSmithKline.; 2010.